Pacira BioSciences, Inc. (PCRX)
$25.76-$0.07 (-0.27%) Today
Latest PCRX Insider Trades
Jonathan Slonin - OfficerOpen-market sale
Jonathan Slonin - OfficerJonathan Slonin - OfficerPacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 19,414 | $443K |
| Grant or award | 15 | 153,747 | |
| Tax withholding / forfeiture | 3 | 16,443 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
39 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jonathan Slonin - Officer | Open-market sale | Common Stock | 3,040 | $23.23 | $71K | |
| Samit Hirawat - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Samit Hirawat - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
| Lauren Riker - Officer | Open-market sale | Common Stock | 6,115 | $23.50 | $144K | |
| Christopher Christie - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
| Christopher Christie - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
 Thomas G. Wiggans - Director | Grant or award | Stock Option (Right to Buy) | 32,675 | $0.00 | - | |
 Alethia Young - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
| Alethia Young - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Michael J. Yang - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
| Michael J. Yang - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Marcelo Bigal - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Marcelo Bigal - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
 Mark Froimson - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
| Mark Froimson - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Laura Brege - Director | Grant or award | Common Stock | 6,405 | $0.00 | - | |
| Laura Brege - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Lauren Riker - Officer | Tax withholding / forfeiture | Common Stock | 3,187 | $22.32 | $71K | |
| Jonathan Slonin - Officer | Tax withholding / forfeiture | Common Stock | 4,728 | $22.32 | $106K | |
| Kristen Williams - Officer | Tax withholding / forfeiture | Common Stock | 8,528 | $22.32 | $190K | |
| Kristen Williams - Officer | Open-market sale | Common Stock | 10,259 | $22.27 | $228K | |
| Shawn Cross - Officer | Option exercise | Common Stock | 12,941 | $16.45 | $213K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 12,941 | $25.16 | $326K | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 12,941 | $0.00 | - | |
| Shawn Cross - Officer | Option exercise | Common Stock | 7,714 | $16.45 | $127K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 7,714 | $25.14 | $194K | |
| Shawn Cross - Officer | Option exercise | Common Stock | 2,845 | $16.45 | $47K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 2,845 | $25.01 | $71K | |
| Shawn Cross - Officer | Option exercise | Common Stock | 1,500 | $16.45 | $25K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 1,500 | $25.01 | $38K | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 7,714 | $0.00 | - | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 2,845 | $0.00 | - | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 1,500 | $0.00 | - | |
 Mark A. Kronenfeld - Director | Grant or award | Common Stock | 6,163 | $0.00 | - | |
| Jonathan Slonin - Officer | Open-market sale | Common Stock | 3,261 | $22.82 | $74K | |
| Mark Froimson - Director | Open-market sale | Common Stock | 500 | $21.81 | $11K | |
| Shawn Cross - Officer | Grant or award | Common Stock | 49,091 | $0.00 | - | |
| Kristen Williams - Officer | Grant or award | Common Stock | 54,546 | $0.00 | - | |
| Brendan Teehan - Officer | Grant or award | Common Stock | 51,714 | $0.00 | - | |
| Lauren Riker - Officer | Grant or award | Common Stock | 19,273 | $0.00 | - | |
| Jonathan Slonin - Officer | Grant or award | Common Stock | 54,546 | $0.00 | - | |
| Frank D. Lee - Officer | Grant or award | Common Stock | 261,818 | $0.00 | - | |
| Lauren Riker - Officer | Tax withholding / forfeiture | Common Stock | 2,751 | $20.54 | $57K | |
| Lauren Riker - Officer | Open-market sale | Common Stock | 4,000 | $20.81 | $83K | |
| Kristen Williams - Officer | Tax withholding / forfeiture | Common Stock | 17,134 | $20.54 | $352K | |
| Kristen Williams - Officer | Open-market sale | Common Stock | 13,137 | $20.53 | $270K | |
| Jonathan Slonin - Officer | Tax withholding / forfeiture | Common Stock | 6,168 | $20.54 | $127K | |
| Brendan Teehan - Officer | Tax withholding / forfeiture | Common Stock | 5,182 | $20.54 | $106K | |
| Frank D. Lee - Officer | Tax withholding / forfeiture | Common Stock | 41,488 | $20.54 | $852K | |
| Samit Hirawat - Director | Grant or award | Stock Option (Right to Buy) | 39,291 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| SLONIN JONATHAN | Officer | 3,040 | $71K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Pacira BioSciences, Inc. (PCRX) had 13 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for PCRX runs to 39 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of PCRX were filed in the last 90 days.
3 insider sales of PCRX were filed in the last 90 days, totaling $443K.
This page tracks PCRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PCRX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
